Drug retention of sarilumab, baricitinib, and tofacitinib in patients with rheumatoid arthritis: the ANSWER cohort study

被引：0
|
作者：
Kosuke Ebina
Toru Hirano
Yuichi Maeda
Wataru Yamamoto
Motomu Hashimoto
Koichi Murata
Akira Onishi
Sadao Jinno
Ryota Hara
Yonsu Son
Hideki Amuro
Tohru Takeuchi
Ayaka Yoshikawa
Masaki Katayama
Keiichi Yamamoto
Makoto Hirao
Yasutaka Okita
Atsushi Kumanogoh
Ken Nakata
机构：
[1] Osaka University,Department of Musculoskeletal Regenerative Medicine
[2] Graduate School of Medicine,Department of Respiratory Medicine and Clinical Immunology
[3] Osaka University,Department of Health Information Management
[4] Graduate School of Medicine,Department of Advanced Medicine for Rheumatic diseases, Graduate School of Medicine
[5] Kurashiki Sweet Hospital,Department of Rheumatology and Clinical Immunology
[6] Kyoto University,The Center for Rheumatic Diseases
[7] Kobe University Graduate School of Medicine,First Department of Internal Medicine
[8] Nara Medical University,Department of Internal Medicine (IV)
[9] Kansai Medical University,Department of Rheumatology
[10] Osaka Medical College,Information Technology Center
[11] Osaka Red Cross Hospital,Department of Orthopaedic Surgery
[12] Wakayama Medical University Hospital,Department of Health and Sport Sciences
[13] Osaka University,undefined
[14] Graduate School of Medicine,undefined
[15] Osaka University,undefined
[16] Graduate School of Medicine,undefined
来源：
Clinical Rheumatology | 2021年 / 40卷
关键词：
ANSWER cohort; Baricitinib; Drug retention; Rheumatoid arthritis; Sarilumab; Tofacitinib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
下载
收藏
页码：2673 / 2680
页数：7
相关论文
共 50 条
  • [41] Cancer risk with tocilizumab/sarilumab, abatacept and rituximab treatment in patients with rheumatoid arthritis: a Danish cohort study
    Westermann, Rasmus
    Cordtz, Rene Lindholm
    Duch, Kirsten
    Mellemkjaer, Lene
    Hetland, Merete Lund
    Magnussen, Bergur
    Dreyer, Lene
    RHEUMATOLOGY, 2024,
  • [42] Time to Discontinuation of Tofacitinib in Rheumatoid Arthritis Patients with and Without Methotrexate: Results from a Rheumatoid Arthritis Cohort
    Movahedi, Mohammad
    Cesta, Angela
    Li, Xiuying
    Keystone, Edward
    Bombardier, Claire
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [43] Comments on the article "Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study"
    Thuy Nhu Thai
    Dawwas, Ghadeer K.
    ARTHRITIS RESEARCH & THERAPY, 2018, 20
  • [44] Relative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in comparison to adalimumab in patients with active rheumatoid arthritis
    Lee, Young Ho
    Song, Gwan Gyu
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2020, 79 (08): : 785 - 796
  • [45] Comments on the article “Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study”
    Thuy Nhu Thai
    Ghadeer K. Dawwas
    Arthritis Research & Therapy, 20
  • [46] DIRECT COMPARISON OF EFFECTIVENESS AND SAFETY OF TOFACITINIB AND BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS IN REAL-WORLD SETTINGS
    Iwamoto, N.
    Suzuki, T.
    Okada, A.
    Fujikawa, K.
    Aramaki, T.
    Mizokami, A.
    Ueki, Y.
    Kawakami, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 581 - 581
  • [47] Obesity might not alter tofacitinib drug survival in rheumatoid arthritis patients
    Erdogan, Esra Kayacan
    Armagan, Berkan
    Ulucakoy, Rezan Kocak
    Orhan, Kevser
    Guven, Serdar Can
    Ulusoy, Bahar Ozdemir
    Konak, Hatice Ecem
    Karakas, Ozlem
    Dagli, Pinar Akyuz
    Atalar, Ebru
    Dogan, Ismail
    Maras, Yuksel
    Omma, Ahmet
    Kucuksahin, Orhan
    Erten, Sukran
    Babaoglu, Hakan
    WIENER KLINISCHE WOCHENSCHRIFT, 2024, : 49 - 55
  • [48] Drug tolerability and reasons for discontinuation of seven biologics in elderly patients with rheumatoid arthritis-The ANSWER cohort study-
    Ebina, Kosuke
    Hashimoto, Motomu
    Yamamoto, Wataru
    Hirano, Toru
    Hara, Ryota
    Katayama, Masaki
    Onishi, Akira
    Nagai, Koji
    Son, Yonsu
    Amuro, Hideki
    Yamamoto, Keiichi
    Maeda, Yuichi
    Murata, Koichi
    Jinno, Sadao
    Takeuchi, Tohru
    Hirao, Makoto
    Kumanogoh, Atsushi
    Yoshikawa, Hideki
    PLOS ONE, 2019, 14 (05):
  • [49] Observational real-world study of patients with rheumatoid arthritis treated with baricitinib and/or tofacitinib in a tertiary hospital, collected in the register of patients and treatments
    Guillen, Elena
    Sabate, Monica
    Ballarin, Elena
    Espartal, Esther
    Lopez, Maria
    Bosch, Montserrat
    Boixareu, Nuria
    Alerany, Carmen
    Diogene, Eduard
    Danes, Immaculada
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 410 - 410
  • [50] Comparative study of the efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib versus methotrexate for disease-modifying antirheumatic drug-naive patients with rheumatoid arthritis
    Sung, Y. -K.
    Lee, Y. H.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2021, 80 (09): : 889 - 898
12345